ECE2009 Poster Presentations Diabetes and Cardiovascular (103 abstracts)
1Endocrinology, University of Bari, Bari, Italy; 2Ematology, University of Bari, Bari, Italy; 3Internal Medicine, University of Bari, Bari, Italy.
Aim: Aim of the study was the evaluation of the effects of chemotherapy on insulin secretion and insulin sensitivity in patients affected by acute leukaemia.
Materials and methods: Thirty-two non-diabetic patients (17 male, 15 female; age 51.1±17.4, range 1676 years; BMI=25.1±3.7, range 18.432.8 kg/m2; 6=18% with a family history of diabetes mellitus) affected by acute leukaemia, 4 LLA (12.5%) and 28 LMA (87.5%), have been submitted to chemotherapy (different combination of mitoxantrone, cytarabine, vincristin, doxorubicin, etoposide and prednisone). Fasting glycaemia, insulin (IRI) and C-peptide have been evaluated before and after chemotherapy as well as HbA1c. Indices of beta cells function and insulin resistance have been calculated.
Results: The results are reported in the Table (P=NS).
Conclusion: All patients showed a basal condition of impaired fasting glucose, hyperglycaemia being frequently observed in critically-ill patients. Preliminary results of our study, however, show that chemotherapy does not influence measures of glycaemic control in non-diabetic patients affected by LLA and LMA.
FG (mmol/l) | IRI (mU/l) | C-pep (mcg/l) | HbA1c (%) | Glyc/Ins (mmol/mU) | HOMA-IR | HOMA β cell function | |
Pre-chemot. | 6.5±0.3 | 19.6±2.9 | 5.2±0.7 | 5.0±0.8 | 0.50±0.34 | 6.0±4.8 | 148±115 |
Post-chemot. | 6.5±0.4 | 18.5±1.8 | 4.6±0.7 | 5.0±0.4 | 0.41±0.22 | 5.8±4.2 | 130±66 |